Charles River Laboratories International's (CRL) "Outperform" Rating Reiterated at William Blair

Charles River Laboratories International (NYSE:CRL - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at William Blair in a report issued on Tuesday,Benzinga reports.

A number of other research firms also recently weighed in on CRL. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Citigroup lowered Charles River Laboratories International from a "neutral" rating to a "sell" rating and cut their target price for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They set a "sell" rating and a $151.00 price target on the stock. Finally, Robert W. Baird lowered their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $214.00.

Charles River Laboratories International Price Performance

CRL stock traded down $11.76 during mid-day trading on Tuesday, reaching $178.38. 1,867,915 shares of the company traded hands, compared to its average volume of 787,064. Charles River Laboratories International has a 52-week low of $175.61 and a 52-week high of $275.00. The company has a market capitalization of $9.12 billion, a P/E ratio of 22.33, a P/E/G ratio of 5.00 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The company has a fifty day moving average price of $193.57 and a 200-day moving average price of $199.32.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.72 EPS. As a group, analysts anticipate that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $32,000. Versant Capital Management Inc increased its holdings in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Assetmark Inc. lifted its holdings in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International in the third quarter valued at about $59,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).